Global Hematological Malignancies Emerging Therapeutics Market.pdf

All rights reserved at BIS Research Inc. 1
H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
res
Focus on Therapeutic Type (Marketed),
Potential Pipeline Products, Indication, and
Region
Analysis and Forecast: 2021-2031
February 2022
Hematological
Malignancies
Emerging
Therapeutics
Market -
A Global and
Regional Analysis
Table of Content

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
Table of Content
Executive Summary..........................................................................20
1. Market .......................................................................................26
1.1 Product Definition............................................................................................27
1.1.1 Monoclonal Antibody (mAB) Therapy: Hematological Malignancies .....27
1.1.2 CAR-T Cell Therapy: Hematological Malignancies...................................27
1.1.3 Inclusion and Exclusion .............................................................................27
1.2 Market Scope ...................................................................................................27
1.2.1 Key Questions Answered in the Report ....................................................28
1.3 Research Methodology ...................................................................................29
1.3.1 Global Hematological Malignancy Emerging Therapeutics Market:
Research Methodology...............................................................................29
1.3.2 Data Sources ...............................................................................................30
1.3.2.1 Primary Data Sources........................................................................................ 30
1.3.2.2 Secondary Data Sources................................................................................... 31
1.3.3 Market Estimation Model ............................................................................32
1.3.4 Criteria for Company Profiling ...................................................................34
1.4 Market Overview ..............................................................................................34
1.4.1 Market Definition .........................................................................................34
1.4.2 Market Footprint and Growth Potential, $Million, 2020-2031...................35
1.4.3 Epidemiology of Hematological Malignancies..........................................36
1.4.3.1 U.S. Epidemiology of Hematological Malignancies ........................................... 37
1.4.3.2 Epidemiology of Hematological Malignancies (Germany, France, Italy, and
Spain (EU4) + U.K.)........................................................................................... 38
1.4.3.3 Japan Epidemiology of Hematological Malignancies......................................... 42
1.4.4 Pipeline Analysis.........................................................................................43
1.4.4.1 By Clinical Phase............................................................................................... 43
1.4.4.2 By Indication ...................................................................................................... 44
1.4.4.2.1 Leukemia.................................................................................................................. 44
1.4.4.2.2 Lymphoma ............................................................................................................... 45

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
1.4.4.2.3 Multiple Myeloma (MM)............................................................................................ 46
1.4.5 Impact of COVID-19 on Global Hematological Malignancies
Emerging Therapeutics Market ..................................................................46
1.4.5.1 Interruption in Research and Clinical Development and Commercial
Operation........................................................................................................... 46
1.4.5.1.1 Research and Clinical Development........................................................................ 46
1.4.5.1.2 Commercial Operation and Access ......................................................................... 47
1.4.5.2 Navigating Crisis Recovery and Looking to the Future...................................... 47
2. Industry Analysis ......................................................................49
2.1 Overview...........................................................................................................50
2.2 Legal Requirements and Frameworks in the U.S..........................................50
2.2.1 Clinical Trial Authorization .........................................................................50
2.2.2 Marketing Authorization .............................................................................50
2.2.3 Post-Authorization Regulations.................................................................52
2.3 Legal Requirements and Frameworks in Europe..........................................53
2.3.1 Centralized Procedure ................................................................................53
2.3.2 Decentralized Procedure ............................................................................54
2.3.3 Mutual-Recognition Procedure ..................................................................54
2.3.4 National Procedure......................................................................................54
2.4 Legal Requirements and Frameworks in Asia-Pacific..................................54
2.4.1 China ............................................................................................................54
2.4.2 Japan............................................................................................................55
2.5 Reimbursement Scenario................................................................................56
2.5.1 U.S. ...............................................................................................................56
2.5.2 Europe..........................................................................................................57
3. Market Dynamics ......................................................................59
3.1 Overview...........................................................................................................60
3.2 Impact Analysis ...............................................................................................60
3.3 Market Drivers..................................................................................................61
3.3.1 Growing Prevalence of Hematological Malignancies...............................61

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
3.3.2 Favorable Regulatory Environment...........................................................62
3.3.3 Increase in Adoption of Precision Medicine in the Field of
Hematological Malignancies ......................................................................63
3.4 Market Restraints.............................................................................................64
3.4.1 High Cost Hindering the Adoption Rate....................................................64
3.4.2 Unfavorable Reimbursement Scenario......................................................64
3.4.3 Safety Concerns Pertaining to Severe Adverse Effects...........................65
3.5 Market Opportunities.......................................................................................65
3.5.1 Massive Scope in Emerging Markets.........................................................65
4. Competitive Landscape .............................................................66
4.1 Overview...........................................................................................................67
4.2 Key Developments and Strategies.................................................................68
4.2.1 Partnerships and Alliances ........................................................................69
4.2.2 Regulatory and Legal Activities .................................................................70
4.2.3 Business Expansions .................................................................................71
4.2.4 Merger and Acquisition Activities..............................................................72
4.2.5 Product Approvals ......................................................................................73
4.2.6 Funding Activities .......................................................................................74
4.3 Market Share Analysis, by Company (2020)..................................................75
5. Role of Companion Diagnostics..................................................77
5.1 Overview...........................................................................................................78
5.2 Drug-Diagnostic Co-Development .................................................................78
5.3 FDA-Approved Companion Diagnostic Tests for Hematological
Malignancies ....................................................................................................80
5.4 Regulatory Framework: Companion Diagnostics (CDx) ..............................81
5.4.1 Overview ......................................................................................................81
5.4.2 Legal Requirements and Frameworks in the U.S. ....................................81
5.4.3 Legal Requirements and Frameworks in Europe .....................................84
5.4.4 Legal Requirements and Frameworks in Asia-Pacific .............................87
5.4.4.1 China ................................................................................................................. 87

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
5.4.4.2 Japan................................................................................................................. 90
5.4.4.3 South Korea....................................................................................................... 91
5.4.4.4 Australia............................................................................................................. 93
6. Global Hematological Malignancies Emerging Therapeutics
Market (by Marketed Drugs), $Million, 2020-2031.......................95
6.1 Overview...........................................................................................................96
6.2 Monoclonal Antibodies ...................................................................................97
6.2.1 Blincyto (Blinatumomab)............................................................................98
6.2.2 Besponsa (Inotuzumab Ozogamicin).........................................................99
6.2.3 Lumoxiti (Moxetumomab Pasudotox)......................................................101
6.2.4 Mylotarg (Gemtuzumab Ozogamicin) ......................................................102
6.2.5 Opdivo (Nivolumab) ..................................................................................103
6.2.6 AiRuiKa (Camrelizumab)...........................................................................104
6.2.7 Tyvyt (Sintilimab).......................................................................................105
6.2.8 Tislelizumab...............................................................................................106
6.2.9 Gazyva (Obinutuzumab) ...........................................................................107
6.2.10 Zynlonta (Loncastuximab Tesirine-lpyl)..................................................109
6.2.11 Darzalex (Daratumumab) ..........................................................................110
6.2.12 Blenrep (Belantamab Mafodotin-blmf).....................................................111
6.2.13 Keytruda (Pembrolizumab).......................................................................112
6.2.13.1 Keytruda for Indication 1 (Hodgkin’s Lymphoma)............................................ 112
6.2.13.2 Keytruda for Indication 2 (Non-Hodgkin’s Lymphoma) .................................... 113
6.2.14 Adcetris (Brentuximab Vedotin)...............................................................114
6.2.14.1 Adcetris for Indication 1 (Hodgkin’s Lymphoma) ............................................. 115
6.2.14.2 Adcetris for Indication 2 (Non-Hodgkin’s Lymphoma) ..................................... 116
6.2.15 Arzerra (Ofatumumab) ..............................................................................116
6.3 CAR-T Cell Therapy .......................................................................................117
6.3.1 Tecartus (Brexucabtagene Autoleucel)...................................................118
6.3.1.1 Tecartus for Indication 1 (Acute Lymphoblastic Leukemia) ............................. 119
6.3.1.2 Tecartus for Indication 2 (Non-Hodgkin’s Lymphoma) .................................... 119

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
6.3.2 Kymriah (Tisagenlecleucel) ......................................................................120
6.3.2.1 Kymriah for Indication 1 (Acute Lymphoblastic Leukemia).............................. 121
6.3.2.2 Kymriah for Indication 2 (Non-Hodgkin’s Lymphoma) ..................................... 122
6.3.3 Yescarta (Axicabtagene Ciloleucel).........................................................123
6.3.4 Breyanzi (Lisocabtagene Maraleucel)......................................................125
6.3.5 Abecma (Idecabtagene Vicleucel)............................................................126
Market (by Potential Pipeline Products), $Million, 2020-2031....127
7.1 Overview.........................................................................................................128
7.2 Monoclonal Antibodies .................................................................................129
7.2.1 Teclistamab................................................................................................130
7.2.2 Iomab-B......................................................................................................133
7.2.2.1 Preliminary Phase II Clinical Trial Results ....................................................... 135
7.2.3 Ublituximab................................................................................................135
7.2.4 CS1001 .......................................................................................................137
7.3 CAR-T Cell Therapy .......................................................................................138
7.3.1 Ciltacabtagene Autoleucel (JNJ-68284528).............................................139
7.3.1.1 Phase IB-II Clinical Trial Results ..................................................................... 141
Market (by Indication), $Million, 2020-2031 ..............................142
8.1 Overview.........................................................................................................143
8.2 Leukemia ........................................................................................................144
8.2.1 Acute Lymphoblastic Leukemia...............................................................144
8.2.2 Chronic Lymphoblastic Leukemia ...........................................................146
8.2.3 Acute Myeloid Leukemia...........................................................................147
8.3 Lymphoma......................................................................................................149
8.3.1 Hodgkin’s Lymphoma...............................................................................150
8.3.2 Non-Hodgkin’s Lymphoma.......................................................................152
8.4 Multiple Myeloma...........................................................................................154
Market (by Region), $Million, 2020-2031...................................156

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
9.1 Overview.........................................................................................................157
9.2 North America................................................................................................158
9.2.1 U.S. .............................................................................................................160
9.2.1.1 Commercialized Products................................................................................ 160
9.2.1.2 Market Size and Forecast, $Million, 2020-2031 .............................................. 162
9.2.2 Canada .......................................................................................................163
1.2 Europe ............................................................................................................165
9.2.3 Germany.....................................................................................................168
9.2.4 Italy .............................................................................................................169
9.2.5 France.........................................................................................................170
9.2.6 U.K. .............................................................................................................171
9.2.7 Spain...........................................................................................................172
9.3 Asia-Pacific ....................................................................................................173
9.3.1 China ..........................................................................................................175
9.3.2 Japan..........................................................................................................177
9.3.3 South Korea ...............................................................................................178
9.4 Rest-of-the-World ..........................................................................................180

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
10. Company Profiles.....................................................................182
10.1 Overview.........................................................................................................183
10.2 AbbVie Inc. .....................................................................................................184
10.2.1 Company Overview ...................................................................................184
10.2.2 Role of AbbVie Inc. in the Global Hematological Malignancies
Emerging Therapeutics Market ................................................................184
10.2.3 Financials...................................................................................................186
10.2.4 Key Insights About Financial Health of the Company ...........................187
10.2.5 SWOT Analysis..........................................................................................188
10.3 Amgen Inc. .....................................................................................................189
10.3.2 Role of Amgen Inc. in the Global Hematological Malignancies
10.3.3 Financials...................................................................................................191
10.3.5 SWOT Analysis..........................................................................................193
10.4 Bristol-Myers Squibb Company ...................................................................194
10.4.2 Role of Bristol-Myers Squibb Company in the Global Hematological
Malignancies Emerging Therapeutics Market.........................................194
10.4.3 Financials...................................................................................................197
10.4.5 SWOT Analysis..........................................................................................199
10.5 F. Hoffmann-La Roche Ltd............................................................................200
10.5.2 Role of F. Hoffmann-La Roche Ltd. in the Global Hematological
10.5.3 Financials...................................................................................................202
10.5.5 SWOT Analysis..........................................................................................205
10.6 Gilead Sciences, Inc. .....................................................................................206

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
10.6.2 Role of Gilead Sciences, Inc. in the Global Hematological
10.6.3 Financials...................................................................................................209
10.6.5 SWOT Analysis..........................................................................................212
10.7 GlaxoSmithKline plc......................................................................................213
10.7.2 Role of GlaxoSmithKline plc in the Global Hematological
10.7.3 Financials...................................................................................................215
10.7.5 SWOT Analysis..........................................................................................217
10.8 Immune-Onc Therapeutics, Inc. ...................................................................218
10.8.2 Role of Immune-Onc Therapeutics, Inc. in the Global Hematological
10.8.3 SWOT Analysis..........................................................................................219
10.9 Johnson & Johnson Services, Inc. ..............................................................220
10.9.2 Role of Johnson & Johnson Services, Inc. in the Global
Hematological Malignancies Emerging Therapeutics Market ...............220
10.9.3 Financials...................................................................................................222
10.9.5 SWOT Analysis..........................................................................................225
10.10 Merck & Co., Inc.............................................................................................226
10.10.1 Company Overview.............................................................................226
10.10.2 Role of Merck & Co., Inc. in the Global Hematological
10.10.3 Financials ............................................................................................228
10.10.4 Key Insights About Financial Health of the Company .....................230

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
10.10.5 SWOT Analysis....................................................................................231
10.11 Novartis International AG..............................................................................232
10.11.2 Role of Novartis International AG in the Global Hematological
10.11.3 Financials ............................................................................................235
10.11.5 SWOT Analysis....................................................................................238
10.12 Pfizer Inc.........................................................................................................239
10.12.2 Role of Pfizer Inc. in the Global Hematological Malignancies
10.12.3 Financials ............................................................................................242
10.12.5 SWOT Analysis....................................................................................244
10.13 Sanofi S.A.......................................................................................................245
10.13.2 Role of Sanofi S.A. in the Global Hematological Malignancies
10.13.3 Financials ............................................................................................246
10.13.4 Key Insights About Financial Health of the Company.....................248
10.13.5 SWOT Analysis....................................................................................249
10.14 Takeda Pharmaceutical Company Limited..................................................250
10.14.2 Role of Takeda Pharmaceutical Company Limited in the Global
Hematological Malignancies Emerging Therapeutics Market ...............250
10.14.3 Financials ............................................................................................252
10.14.5 SWOT Analysis....................................................................................255

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
List of Figures
Figure 1: Hematological Malignancies Drugs Approved by U.S. FDA (2015-2021)
Figure 2: Hematological Malignancies Drugs Global Clinical Trials (by Phase)
Figure 3: Global Hematological Malignancies Emerging Therapeutics Market (by Marketed
Drugs), $Million, 2020-2031
Figure 4: Global Hematological Malignancies Emerging Therapeutics Market: Impact Analysis
Figure 5: Global Hematological Malignancies Emerging Therapeutics Market (by Potential
Pipeline Products), $Million, 2020-2031
Figure 6: Global Hematological Malignancies Emerging Therapeutics Market (by Indication),
$Million, 2020-2031
Figure 7: Global Hematological Malignancies Emerging Therapeutics Market (by Region),
$Million, 2020-2031
Figure 8: Global Hematological Malignancies Emerging Therapeutics Market: Segmentation
Figure 9: Global Hematological Malignancies Emerging Therapeutics Market: Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Step by Step Approach
Figure 13: Global Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-
2031
Figure 14: Types of Hematological Malignancies
Figure 15: Hematological Malignancies Prevalence in the U.S., 2019-2031
Figure 16: Hematological Malignancies Incidence in the U.S., 2019-2031
Figure 17: Percentage of Hematological Malignancies Prevalence (by Country), 2019 and 2031
Figure 18: Hematological Malignancies Prevalence in EU4+U.K., 2019-2031
Figure 19: Percentage of Hematological Malignancies Incidence (by Country), 2019 and 2031
Figure 20: Hematological Malignancies Incidence in EU4 + U.K., 2019-2031
Figure 21: Hematological Malignancies Prevalence in Japan, 2019-2031
Figure 22: Hematological Malignancies Incidence in Japan, 2019-2031
Figure 23: Hematological Malignancies Emerging Therapies: Developmental Phases
Figure 24: Emerging Therapeutics for Leukemia (by Developmental Phase)
Figure 25: Emerging Therapeutics for Lymphoma (by Developmental Phase)
Figure 26: Emerging Therapeutics for Multiple Myeloma (by Developmental Phase)
Figure 27: Key Steps to Navigate Crisis Recovery
Figure 28: Process for Obtaining Marketing Authorization
Figure 29: Current Reimbursement Scenario in Europe
Figure 30: Prevalence of Hematological Malignancies (2015-2019)
Figure 31: Share of Key Developments and Strategies, January 2019-December 2021
Figure 32: Partnerships and Alliances (by Company), January 2019-December 2021
Figure 33: Regulatory and Legal Activities (by Company), January 2019-December 2021
Figure 34: Business Expansions (by Company), January 2019-December 2021

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
Figure 35: Merger and Acquisition Activities (by Company), January 2019-December 2021
Figure 36: Product Approvals (by Company), January 2019-December 2021
Figure 37: Market Share Analysis (by Company), 2020
Figure 38: Drug-Diagnostic Co-Development Model
Figure 39: FDA Guidance Pertaining to CDx Approval
Figure 40: Components Considered for Clinical Evidence as per the IVDR
Figure 41: Medical Device Regulatory Approval Process in China
Figure 42: Process of Medical Device Designation by MHLW and PMDA
Figure 43: Medical Device Regulatory Approval Process in South Korea
Figure 44: Classification of IVD Devices
Figure 45: Medical Device (IVDs) Regulatory Approval Process in Australia
Figure 46: Global Hematological Malignancies Emerging Therapeutics Market (by Marketed
Drugs), $Million, 2020-2031
Figure 47: Global Hematological Malignancies Emerging Therapeutics Market (by Monoclonal
Antibodies), $Million, 2020-2031
Figure 48: Global Revenue for Blincyto, $Million, 2020-2031
Figure 49: Global Revenue for Besponsa, $Million, 2020-2031
Figure 50: Global Revenue for Lumoxiti, $Million, 2020-2031
Figure 51: Global Revenue for Mylotarg, $Million, 2020-2031
Figure 52: Global Revenue for Opdivo, $Million, 2020-2031
Figure 53: Global Revenue for AiRuiKa, $Million, 2020-2031
Figure 54: Global Revenue for Tyvyt, $Million, 2020-2031
Figure 55: Global Revenue for Tislelizumab, $Million, 2020-2031
Figure 56: Global Revenue for Gazyva, $Million, 2020-2031
Figure 57: Global Revenue for Zynlonta, $Million, 2020-2031
Figure 58: Global Revenue for Darzalex, $Million, 2020-2031
Figure 59: Global Revenue for Blenrep, $Million, 2020-2031
Figure 60: Global Revenue for Keytruda, $Million, 2020-2031
Figure 61: Global Revenue for Keytruda (Hodgkin’s Lymphoma), $Million, 2020-2031
Figure 62: Global Revenue for Keytruda (Non-Hodgkin’s Lymphoma), $Million, 2020-2031
Figure 63: Global Revenue for Adcetris, $Million, 2020-2031
Figure 64: Global Revenue for Adcetris (Hodgkin’s Lymphoma), $Million, 2020-2031
Figure 65: Global Revenue for Adcetris (Non-Hodgkin’s Lymphoma), $Million, 2020-2031
Figure 66: Global Hematological Malignancies Emerging Therapeutics Market (by CAR-T Cell
Therapy), $Million, 2020-2031
Figure 67: Global Revenue for Tecartus, $Million, 2020-2031
Figure 68: Global Revenue for Tecartus (Acute Lymphoblastic Leukemia), $Million, 2020-2031
Figure 69: Global Revenue for Tecartus (Non-Hodgkin’s Lymphoma), $Million, 2020-2031
Figure 70: Global Revenue for Kymriah, $Million, 2020-2031
Figure 71: Global Revenue for Kymriah (Acute Lymphoblastic Leukemia), $Million, 2020-2031

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
Figure 72: Global Revenue for Kymriah (Non-Hodgkin’s Lymphoma), $Million, 2020-2031
Figure 73: Global Revenue for Yescarta, $Million, 2020-2031
Figure 74: Global Revenue for Breyanzi, $Million, 2020-2031
Figure 75: Global Revenue for Abecma, $Million, 2020-2031
Pipeline Products), $Million, 2020-2031
Pipeline Products), by Monoclonal Antibodies), $Million, 2020-2031
Figure 78: Global Revenue for Teclistamab, $Million, 2020-2031
Figure 79: Teclistamab Phase I Clinical Trial Design for Relapsed or Refractory Multiple Myeloma
Figure 80: Teclistamab Phase II Clinical Trial Design for Relapsed or Refractory Multiple
Myeloma
Figure 81: Global Revenue for Iomab-B, $Million, 2020-2031
Figure 82: Iomab-B Phase III Clinical Trial Design for Relapsed or Refractory Acute Myeloid
Leukemia
Figure 83: Global Revenue for Ublituximab, $Million, 2020-2031
Figure 84: Ublituximab Phase I/II Clinical Trial Design for Relapsed or Refractory B-Cell Non-
Hodgkin’s Lymphoma
Figure 85: Global Revenue for CS1001, $Million, 2020-2031
Figure 86: CS1001 Phase II Clinical Trial Design for Relapsed or Refractory B-cell Hodgkin’s
Lymphoma
Figure 87: Global Revenue for Ciltacabtagene Autoleucel, $Million, 2020-2031
Figure 88: Ciltacabtagene Autoleucel (JNJ-68284528) Phase Ib-II Clinical Trial Design for
Relapsed or Refractory Multiple Myeloma
Figure 89: Global Hematological Malignancies Emerging Therapeutics Market (by Indication),
$Million, 2020-2031
Figure 90: Global Hematological Malignancies Emerging Therapeutics Market (by Indication, by
Leukemia), $Million, 2020-2031
Figure 91: Global Hematological Malignancies Emerging Therapeutics Market (by Acute
Lymphoblastic Leukemia), $Million, 2020-2031
Figure 92: Global Hematological Malignancies Emerging Therapeutics Market (by Chronic
Lymphoblastic Leukemia), $Million, 2020-2031
Figure 93: Global Hematological Malignancies Emerging Therapeutics Market (by Acute Myeloid
Leukemia), $Million, 2020-2031
Figure 94: Global Hematological Malignancies Emerging Therapeutics Market (by Lymphoma),
$Million, 2020-2031
Figure 95: Global Hematological Malignancies Emerging Therapeutics Market (by Hodgkin’s
Lymphoma), $Million, 2020-2031
Figure 96: Global Hematological Malignancies Emerging Therapeutics Market (by Non-Hodgkin’s
Lymphoma), $Million, 2020-2031
Figure 97: Global Hematological Malignancies Emerging Therapeutics Market (by Multiple
Myeloma), $Million, 2020-2031
Figure 98: Global Hematological Malignancies Emerging Therapeutics Market (by Region),
$Million, 2020-2031
Figure 99: North America Hematological Malignancies Emerging Therapeutics Market, $Million,
2020-2031

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
Figure 100: North America: Market Dynamics
Figure 101: North America Hematological Malignancies Emerging Therapeutics Market, (by
Country), $Million, 2020 and 2031
Figure 102: U.S. Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031
Figure 103: Canada Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-
2031
Figure 104: Europe Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-
2031
Figure 105: Europe: Market Dynamics
Figure 106: Europe Hematological Malignancies Emerging Therapeutics Market, (by Country),
$Million, 2020 and 2031
Figure 107: Germany Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-
2031
Figure 108: Italy Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031
Figure 109: France Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-
2031
Figure 110: U.K. Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031
Figure 111: Spain Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-
2031
Figure 112: Asia-Pacific Hematological Malignancies Emerging Therapeutics Market, $Million,
2020-2031
Figure 113: Asia-Pacific: Market Dynamics
Figure 114: Asia-Pacific Hematological Malignancies Emerging Therapeutics Market (by Country),
$Million, 2020 and 2031
Figure 115: China Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-
2031
Figure 116: Japan Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-
2031
Figure 117: South Korea Hematological Malignancies Emerging Therapeutics Market, $Million,
2020-2031
Figure 118: Rest-of-the-World Hematological Malignancies Emerging Therapeutics Market,
$Million, 2020-2031
Figure 119: Total Number of Companies Profiled
Figure 120: AbbVie Inc.: Pre-Clinical and Clinical Assets
Figure 121: AbbVie Inc.: Overall Financials, $Million, 2018-2020
Figure 122: AbbVie, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 123: AbbVie Inc.: R&D Expenditure, $Million, 2018-2020
Figure 124: AbbVie Inc.: SWOT Analysis
Figure 125: Amgen Inc.: Commercialized Therapy
Figure 126: Amgen Inc.: Pre-Clinical and Clinical Assets
Figure 127: Amgen Inc.: Overall Financials, $Million, 2018-2020
Figure 128: Amgen Inc.: Revenue (by Region), $Million, 2018-2020
Figure 129: Amgen Inc.: R&D Expenditure, $Million, 2018-2020
Figure 130: Amgen Inc.: SWOT Analysis

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
Figure 131: Bristol-Myers Squibb Company: Commercialized Therapies
Figure 132: Bristol-Myers Squibb Company: Pre-Clinical and Clinical Assets
Figure 133: Bristol-Myers Squibb Company: Overall Financials, $Million, 2018-2020
Figure 134: Bristol-Myers Squibb Company: Revenue (by Region), $Million, 2018-2020
Figure 135: Bristol-Myers Squibb Company: R&D Expenditure, $Million, 2018-2020
Figure 136: Bristol-Myers Squibb Company: SWOT Analysis
Figure 137: F. Hoffmann-La Roche Ltd.: Commercialized Therapy
Figure 138: F. Hoffmann-La Roche Ltd.: Pre-Clinical and Clinical Assets
Figure 139: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2018-2020
Figure 140: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2018-2020
Figure 141: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2018-2020
Figure 142: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2018-2020
Figure 143: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 144: Gilead Sciences, Inc.: Commercialized Therapies
Figure 145: Gilead Sciences, Inc.: Pre-Clinical and Clinical Assets
Figure 146: Gilead Sciences, Inc.: Overall Financials, $Million, 2018-2020
Figure 147: Gilead Sciences, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 148: Gilead Sciences, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 149: Gilead Sciences, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 150: Gilead Sciences, Inc.: SWOT Analysis
Figure 151: GlaxoSmithKline plc: Commercialized Therapy
Figure 152: GlaxoSmithKline plc: Overall Financials, $Million, 2018-2020
Figure 153: GlaxoSmithKline plc: Revenue (by Segment), $Million, 2018-2020
Figure 154: GlaxoSmithKline plc: Revenue (by Region), $Million, 2018-2020
Figure 155: GlaxoSmithKline plc: R&D Expenditure, $Million, 2018-2020
Figure 156: GlaxoSmithKline plc: SWOT Analysis
Figure 157: Immune-Onc Therapeutics, Inc.: Pre-Clinical and Clinical Assets
Figure 158: Immune-Onc Therapeutics, Inc.: SWOT Analysis
Figure 159: Johnson & Johnson Services, Inc.: Commercialized Therapy
Figure 160: Johnson & Johnson Services, Inc.: Pre-Clinical and Clinical Assets
Figure 161: Johnson & Johnson Services, Inc.: Overall Financials, $Million, 2018-2020
Figure 162: Johnson & Johnson Services, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 163: Johnson & Johnson Services, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 164: Johnson & Johnson Services, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 165: Johnson & Johnson Services, Inc.: SWOT Analysis
Figure 166: Merck & Co., Inc.: Commercialized Therapy
Figure 167: Merck & Co., Inc.: Pre-Clinical and Clinical Assets
Figure 168: Merck & Co., Inc.: Overall Financials, $Million, 2018-2020
Figure 169: Merck & Co., Inc.: Revenue (by Segment), $Million, 2018-2020

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
Figure 170: Merck & Co., Inc.: Revenue (by Region), $Million, 2018-2020
Figure 171: Merck & Co., Inc.: R&D Expenditure, $Million, 2018-2020
Figure 172: Merck & Co., Inc.: SWOT Analysis
Figure 173: Novartis International AG: Commercialized Therapy
Figure 174: Novartis International AG: Pre-Clinical and Clinical Assets
Figure 175: Novartis International AG: Overall Financials, $Million, 2018-2020
Figure 176: Novartis International AG: Revenue (by Segment), $Million, 2018-2020
Figure 177: Novartis International AG: Revenue (by Region), $Million, 2018-2020
Figure 178: Novartis International AG: R&D Expenditure, $Million, 2018-2020
Figure 179: Novartis International AG: SWOT Analysis
Figure 180: Pfizer Inc.: Commercialized Therapy
Figure 181: Pfizer Inc.: Pre-Clinical and Clinical Assets
Figure 182: Pfizer Inc.: Overall Financials, $Million, 2018-2020
Figure 183: Pfizer Inc.: Revenue (by Region), $Million, 2018-2020
Figure 184: Pfizer Inc.: R&D Expenditure, $Million, 2018-2020
Figure 185: Pfizer Inc.: SWOT Analysis
Figure 186: Sanofi S.A.: Pre-Clinical and Clinical Assets
Figure 187: Sanofi SA: Overall Financials, $Million, 2018-2020
Figure 188: Sanofi S.A.: Revenue (by Segment), $Million, 2018-2020
Figure 189: Sanofi S.A.: Revenue (by Region), $Million, 2018-2020
Figure 190: Sanofi S.A.: R&D Expenditure, $Million, 2018-2020
Figure 191: Sanofi S.A.: SWOT Analysis
Figure 192: Takeda Pharmaceutical Company Limited.: Commercialized Therapy
Figure 193: Takeda Pharmaceutical Company Limited: Pre-Clinical and Clinical Assets
Figure 194: Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2018-2020
Figure 195: Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2018-2020
Figure 196: Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2018-2020
Figure 197: Takeda Pharmaceutical Company Limited: SWOT Analysis

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
List of Tables
Table 1: Cost of Selective Hematological Malignancies Therapeutics in U.S.
Table 2: Likert Scale
Table 3: Impact Analysis of Market Drivers
Table 4: Impact Analysis of Market Restraints
Table 5: Prominent FDA-Approved CDx Tests for Hematological Malignancies
Table 6: Classification Rules of IVDs under IVDR
Table 7: Registration Criteria for IVD Medical Devices as per the NMPA
Table 8: Hematological Malignancies Therapeutics Drugs for Acute Lymphoblastic Leukemia
Table 9: Hematological Malignancies Therapeutics Drugs for Chronic Lymphoblastic Leukemia
Table 10: Hematological Malignancies Therapeutics Drugs for Acute Myeloid Leukemia
Table 11: Hematological Malignancies Therapeutics Drugs for Hodgkin’s Lymphoma
Table 12: Hematological Malignancies Therapeutics Drugs for Non-Hodgkin’s Lymphoma
Table 13: Hematological Malignancies Therapeutics Drugs for Multiple Myeloma
Table 14: List of Selective Hematological Malignancies Commercialized Products in the U.S.
Table 15: Canada Hematological Malignancies Commercialized Products
Table 16: List of Selective Hematological Malignancies Commercialized Products in Europe
Table 17: List of Selective Hematological Malignancies Commercialized Products in China
Table 18: List of Selective Hematological Malignancies Commercialized Products in Japan
Table 19: List of Selective Hematological Malignancies Commercialized Products in South Korea
Table 20: Blincyto (Blinatumomab): Indications
Table 21: Opdivo (Nivolumab) and Breyanzi (Lisocabtagene Maraleucel): Indications
Table 22: Gazyva (Obinutuzumab): Indications
Table 23: Yescarta (Axicabtagene ciloleucel) and Tecartus (Brexucabtagene autoleucel):
Indications
Table 24: Blenrep (Belantamab mafodotin): Indications
Table 25: Darzalex (Daratumumab): Indications
Table 26: Keytruda (Pembrolizumab): Indications
Table 27: Kymriah (Tisagenlecleucel): Indications
Table 28: Besponsa (Inotuzumab ozogamicin) and Mylotarg (Gemtuzumab Ozogamicin):
Indications
Table 29: Adcetris (Brentuximab vedotin): Indications

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates, and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

H
e
m
a
t
o
l
o
g
i
c
a
l
M
a
l
i
g
n
a
n
c
i
e
s
E
m
e
r
g
i
n
g
T
h
e
r
a
p
e
u
t
i
c
s
M
a
r
k
e
t
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

Global Hematological Malignancies Emerging Therapeutics Market.pdf

Recommended

Recommended

More Related Content

Similar to Global Hematological Malignancies Emerging Therapeutics Market.pdf

Similar to Global Hematological Malignancies Emerging Therapeutics Market.pdf (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Global Hematological Malignancies Emerging Therapeutics Market.pdf